Work

A simple, 3-factor pre-treatment score (Toranomon Prognostic Score) robustly stratifies progression risk in patients with relapsed/refractory large B-cell lymphoma receiving commercial CAR T-cell therapy: A real-world analysis

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-1942

Authors: Rikako Tabata, Daisuke Kaji, Go Yamamoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Hisashi Yamamoto, Yuki Asano-Mori, Atsushi Wake, Shuichi Taniguchi, Naoyuki Uchida

Institution: Toranomon Hospital

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417005950

Cites:

Cited by:

Related to: